Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

NCT04319783 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Advanced Prostate Carcinoma
Cancer of Prostate
PSA
Castrate Resistant Prostate Cancer

Interventions

DRUG: Darolutamide
RADIATION: Radiotherapy

Sponsor

Trans Tasman Radiation Oncology Group

Collaborators

[object Object]
[object Object]